Connective Tissue Disease Patients With Pulmonary Hypertension

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Aug 7, 2023

Keywords

ClinConnect Summary

This clinical trial is focusing on adult patients who have connective tissue diseases (like lupus or rheumatoid arthritis) and are also suspected to have pulmonary hypertension, a condition where high blood pressure affects the lungs. The study aims to gather important information about these patients, including their health history, test results, and blood samples. Participants will visit the clinic at the start of the study and then again at 3, 6, and 12 months to provide additional blood samples and complete some questionnaires about their health.

To be eligible for this trial, patients must have a confirmed connective tissue disease and meet specific criteria for pulmonary hypertension. This means they need to have certain test results confirming the condition. However, individuals with other significant lung or heart diseases, or those under 18 years old, will not be able to participate. The trial is not yet recruiting patients, but it will provide valuable insights into how these diseases are connected and may help improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
• • PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)\>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）\>2 Wood
• Exclusion Criteria:
• • significant interstitial lung disease or chronic obstructive pulmonary disease;
• • left heart disease or congenital heart disease associated with pulmonary hypertension;
• • chronic thromboembolic pulmonary hypertension;
• • portal hypertension;
• • drug or toxin exposure;
• • HIV infection;
• • any other diseases known to be associated with PAH;
• • age\<18 years.